Background-There are evidence-based guidelines for staging of patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), but we are not aware of any evidence comparing the strategy of complete revascularization (CR) with PCI in the index admission versus the strategy of staging in a subsequent admission for patients with coronary artery disease without STEMI. Methods and Results-PCI patients without STEMI undergoing PCI in New York between 2007 and 2009 were separated into 2 groups: those with acute coronary syndrome but no STEMI, and those without acute coronary syndrome. For each group, patients who underwent CR in the index admission were then propensity matched to patients staged within 60 days to obtain CR based on 17 patient risk factors related to longer-term mortality, and 3-year mortality rates were compared for the propensity-matched groups. Outcomes were also compared for preselected subgroups. For propensitymatched patients without acute coronary syndrome, the all-cause mortality rates at 3 years for patients who underwent CR in the index hospitalization and patients staged for CR within 60 days of discharge were 5.62% and 5.97%, P=0.93, respectively. For propensity-matched patients with acute coronary syndrome but without STEMI, the all-cause mortality rates at 3 years for patients who underwent CR in the index hospitalization and patients staged for CR within 60 days of discharge were 6.59% and 5.92%, P=0.41, respectively. Conclusions-Patients with coronary artery disease without STEMI do not have significantly lower 3-year mortality rates with staged PCI than when they undergo CR in the index admission. (Circ Cardiovasc Interv. 2013;6:12-20.)
R ecent studies have demonstrated that multivessel disease patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) experience better outcomes with culprit vessel PCI followed by staged PCI of other diseased vessels. [1] [2] [3] These findings are reflected in the current American College of Cardiology/American Heart Association guidelines for the management of patients with STEMI recommending primary PCI as the treatment of choice. 4, 5 For most patients with multivessel disease who undergo primary PCI for STEMI, it is recommended that only the culprit vessel be treated, and that other diseased vessels be addressed in an elective procedure at another time. Acute multivessel PCI is recommended during the index procedure only for patients with hemodynamic compromise. 4, 5 However, the guidelines do not speak to the advisability of staging for patients without STEMI. It is very important to know whether staging yields significantly better outcomes for patients without STEMI because the Centers for Medicare and Medicaid Services is experimenting with bundled payment initiatives whereby hospitals and physicians would not receive additional payment for staged readmissions. 6
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The purpose of this study is to examine 3-year mortality outcomes for patients with multivessel disease without STEMI who undergo complete revascularization (CR) in the index hospitalization with similar patients who are staged to receive CR after discharge but within 2 months of the index hospitalization. Patients with acute coronary syndrome (ACS) (unstable angina, or recent myocardial infarction within 7 days, without STEMI) and patients without ACS are analyzed separately, in case the conclusions are different for these 2 fundamentally different groups.
Methods

Databases
Data were obtained from PCIs Reporting System of New York State, a mandatory registry in New York that was initially developed in 1991 that contains detailed information for each patient undergoing PCI in the state on demographics; preprocedural risk factors; periprocedural complications; types of devices used; extent of disease and lesions treated; dates of admission, discharge and procedure; discharge disposition and destination; and hospital and operator identifiers. There is also a variable that denotes in the index admission for PCI whether patients are intended to be staged at a later date, and a variable in subsequent admissions for PCI that indicates the procedure performed is a staged procedure. For purposes of this study, a procedure is regarded as staged only if it is coded as intended in the index admission and coded as staged in the subsequent admission. Furthermore, the PCI in the second admission is required to be an elective procedure that is not in the target vessel of the index PCI.
These data are matched to New York administrative data for purposes of auditing completeness and the accuracy of in-hospital mortality reporting. Also, medical records are audited by using a review agent of New York State Department of Health to ensure accuracy of reporting of risk factors and complications. The Percutaneous Coronary Interventions Reporting System data were also matched to the social security death file and vital statistics data of New York, so that these patients could be followed after discharge for evidence of subsequent mortality for up to 3 years after the index procedure.
Patients, Hospitals, and Outcomes Patients
A total of 15 955 patients with multivessel disease who did not have left main artery disease or a chronic total occlusion in any major coronary artery underwent CR with PCI at the index hospitalization or were scheduled for staged PCI in nonfederal New York hospitals between January 1, 2007, and December 31, 2009 . Exclusions were patients who had any major cardiac complication during the index hospitalization before obtaining CR (63 patients); patients who underwent incomplete multivessel (2 vessel) revascularization during the index PCI and were scheduled for a staged CR (629); patients who had previous cardiac surgery (192); patients who were emergency cases: STEMI within 0 to 24 hours, hemodynamically unstable, shock, malignant ventricular arrhythmia (2074); patients who had STEMI within 1 to 7 days (847); patients who had emergency admission status without an ACS diagnosis (19); patients who had an organ transplant (48); patients who had renal dialysis (279), a glomerular filtration rate <30 mL/min per 1.73 m 2 (458) or staged PCI patients who had high volume contrast (5 mg/kg) use in the index PCI (257); staged PCI patients who had any major complication during the index PCI (78); patients who underwent a staged PCI >60 days (478); or patients who did not undergo a staged PCI although scheduled for staging (1877).
The final ACS study sample consisted of 5193 patients. Of these, 4122 underwent CR during the index hospitalization, 1062 underwent staged CR within 60 days after discharge, and 9 patients were scheduled for a staged PCI but died within 60 days without being staged. The final non-ACS study sample had 5181 patients. Of these, 3600 underwent CR during the index hospitalization, 1577 underwent staged CR within 60 days of discharge, and 4 patients were scheduled for a staged PCI but died within 60 days without being staged.
A total of 49 hospitals, all nonfederal hospitals in which PCI was performed for ACS and patients without ACS during the study period,
WHAT IS KNOWN
• There are evidence-based guidelines for staging of patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention, but we are not aware of any evidence comparing the strategy of complete revascularization with percutaneous coronary intervention in the index admission versus the strategy of staging in a subsequent admission for patients with coronary artery disease without ST-elevation myocardial infarction.
WHAT THE STUDY ADDS
• Patients with coronary artery disease without ST-elevation myocardial infarction do not have significantly lower 3-year mortality rates with staged percutaneous coronary intervention than when they undergo complete revascularization in the index admission. were included in the study. Outcomes included mortality at 6 months, 1, 2, and 3 years.
Statistical Analyses
The objectives of the analyses were to determine whether there are differences in longer-term (3-year) mortality based on whether patients with multivessel disease without STEMI were staged to undergo subsequent PCI with CR after discharge from the index hospitalization versus patients who received CR during the index hospitalization. For this purpose, the group of patients without STEMI was subdivided into 2 groups: (1) patients with ACS (recent acute myocardial infarction within the previous 7 days, or unstable angina); and (2) all other patients without STEMI. The analyses to be described were conducted separately for each of these groups.
Because patients were not randomized by staging versus nonstaging, we identified patient characteristics that were potentially related to staging decision as well as being potential predictors of adverse outcomes. We compared the prevalences of these risk factors among staged and unstaged CR patients using χ 2 tests and found that many prevalences were significantly different for the 2 groups. Consequently, we used propensity score matching to identify a set of matched staged and nonstaged pairs, so that confounding could be reduced. Patients were matched on the basis of age, sex, body surface area, race, ethnicity, admission type, primary payer, previous myocardial infarction, Canadian Cardiovascular Society angina class, ejection fraction, renal dysfunction (reduced glomerular filtration rate), extent of cardiovascular disease, congestive heart failure, congestive obstructive pulmonary disease, peripheral vascular disease, cerebrovascular disease, and diabetes mellitus. The propensity score was derived by using a logistic regression model to predict the probability of being staged rather than not staged for each patient as a function of the risk factors just noted.
A global optimization matching algorithm (one that picks pairs of staged and unstaged CR patients, so that the sum of distances between the propensity scores of the paired patients is minimized) was used, 7 with matching allowed only if the difference in the logits of the matched propensity scores was <0.6 times the SDs of the scores. [8] [9] [10] Matching was on a 1:1 basis, each matched pair was unique, and data for unmatched patients were not used in subsequent analyses. The balance between patient characteristics in the paired groups was tested by computing the standardized differences between the 2 groups (staged CR and unstaged CR) for each of the matched characteristics. A difference of <0.1 (10%) was regarded as acceptable. 11 The propensity-matched pairs were then used to analyze differences in outcomes between the 2 groups. Methods were used to compare mortality of staged and unstaged patients for a 3-year follow-up period with Kaplan-Meier plots and a log-rank test.
The impact of treatment type on mortality was also tested for a few preselected risk factors of interest (age, number of vessels diseased, ejection fraction, renal dysfunction, Medicaid insurance) to determine whether the differential outcomes for staged and unstaged patients differed according to these preselected factors. For each subgroup of each factor (eg, ejection fraction <40%), a Cox proportional hazards model was fit, including treatment type (staged versus unstaged) and other significant (P<0.05) risk factors for mortality that were identified using a backward selection process. The assumptions of the Cox model were confirmed using graphical methods. 12 Variation among hospitals in the percentage of patients completely revascularized in the index admission versus staged to be CR in a subsequent admission was examined for both ACS and non-ACS patients. All analyses were performed according to the intention to treat, with patients who were intended to be staged who died within 60 days after the index procedure before staging being regarded as staged patients. However, the analyses were repeated with these patients removed from the study group, and there were no changes in statistical significance for 3-year mortality. All tests were 2-sided and conducted at the 0.05 level, and all analyses were conducted in SAS 9.1 (SAS Institute, Cary, NC).
Results
For patients with ACS who either received CR during the index hospitalization or within 60 days after discharge, 79.4% were in the former group and 20.6% were in the latter group. For patients without ACS, 69.5% received CR during the index admission and 30.5% of patients were staged to receive CR within 60 days after the index admission ( Figure 1 ). As noted in Tables 1 and 2 , there were many significant differences between the staged and unstaged patients before propensity matching. For non-ACS patients ( Table 1) , age in the 60s and 70s, lower body surface areas, racial minorities, Hispanics, elective admissions, Medicaid status, absence of a previous myocardial infarction, class II angina, higher ejection fractions, 3-vessel disease, previous (but not current) congestive heart failure, and renal dysfunction were associated with more staging. For patients with ACS (Table 2) , age in the 60s and 70s, racial minorities, Hispanics, Medicaid status, no previous acute myocardial infarction, higher ejection fractions, 3-vessel disease, diabetes mellitus, and renal dysfunction were associated with more staging.
Propensity matching succeeded in matching 1040 of the 1071 staged patients with ACS with other ACS patients who underwent CR in the index hospitalization, and 1532 of the 1581 staged patients without ACS with their non-ACS counterparts who underwent CR in the index hospitalization. As indicated in Tables 3 and 4 , after propensity matching, there were no longer any statistically significant differences in risk factor prevalence between the staged and unstaged patients, and the standardized difference was well below the recommended maximum value of 10% for every risk factor. 11 Figure 2 presents the outcomes for ACS and non-ACS patients undergoing CR in the index hospitalization and staged for CR within 60 days of discharge after the index hospitalization. For propensity-matched patients without ACS, the allcause mortality rates at 3 years for patients who underwent CR in the index hospitalization and patients staged for CR within 60 days of discharge were 5.62% and 5.97%, P=0.68, respectively. For propensity-matched patients with ACS, the all-cause mortality rates at 3 years for patients who were CR in the index hospitalization and patients staged for CR within 60 days of discharge were 6.59% and 5.92%, P=0.22, respectively. As indicated in both tables, the mortality rates for the 2 groups were also very similar at 6 months, 1, and 2 years.
When we compared ACS and non-ACS outcomes for each of the 2 strategies for preselected subgroups of patients aged above and below 75 years, number of vessels diseased, ejection fraction above and below 40%, glomerular filtration rate, and Medicaid status, there were no statistically significant differences for patient subgroups for either the patients with ACS or the patients without ACS (data not shown).
For patients with ACS, the percentages with radial access were 10.9% for patients with CR in the index hospitalization and 9.7% for staged CR patients (P=0.25). For patients with stable coronary artery disease, the percentages with radial access were 11.9% for patients with CR in the index hospitalization and 8.5% for staged CR patients (P<0.0001). The statistical power to detect propensity-matched mortality differences was very low. In patients without ACS, there were only 15 pairs of patients with radial access who were matched, and in the ACS group only 7 pairs with radial access were matched.
The variation in the choice of PCI strategy used by hospitals to treat multivessel disease patients without STEMI is presented in Figure 3 . For patients without ACS and hospitals with volumes of multivessel disease patients without STEMI undergoing CR that is >20, 7 hospitals (17.5%) had <60% of their patients undergoing CR during the index admission after risk adjusting for patient characteristics most related to CR strategy, whereas 9 hospitals (22.5%) had >90% of their patients undergoing CR during the index admission after risk adjustment. For patients with ACS (Figure 4 ), 10 hospitals (23.3%) had lower than a risk adjusted 70% of their patients undergoing CR during the index admission, and 17 hospitals (39.5%) used this strategy for at least 90% of their patients after risk adjustment. 
Discussion
There is ample evidence followed by American College of Cardiology/American Heart Association guidelines that establish that the best way of treating multivessel disease STEMI patients with PCI is to treat the culprit lesion in the index admission followed by a staged PCI in a subsequent admission. [1] [2] [3] [4] [5] For example, in the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial, Kornowski et al 1 found that 1-time CR of culprit and nonculprit lesions of STEMI patients with PCI was inferior to culprit lesion PCI followed by staged nonculprit lesion PCI with a 1-year mortality of 9.2% versus 2.3%, hazard ratio, 4.1; 95% confidence interval (1.93-8.86 ). Also, cardiac mortality and stent thrombosis rates were significantly higher with 1-time CR. 1 In a meta-analysis of the above 2 strategies for treated multivessel disease STEMI patients plus a culprit vessel-only strategy in 4 prospective and 14 retrospective studies, Vlaar et al 2 found that staged PCI was associated with lower short-and long-term mortality than the other 2 approaches. In New York, Hannan et al 3 found that for STEMI patients without hemodynamic compromise, culprit vessel PCI during the index procedure was associated with lower in-hospital mortality than multivessel PCI during the index procedure (0.9% versus 2.4%, P=0.04). Also, STEMI patients undergoing staged PCI within 60 days of the index procedure had significantly lower 1-year mortality than patients undergoing culprit vessel-only PCI (1.3% versus 3.3%, P=0.04). 3 However, we have been unable to find any studies or any guidelines that treat multivessel disease patients without STEMI with PCI. The options for treatment are the same CR in the same hospitalization, CR with staging of nonculprit vessels in a readmission, and culprit vessel PCI in the index admission without CR. Earlier studies in New York have demonstrated that for all patients with PCI in general, CR with PCI yields better outcomes than incomplete revascularization, and that this finding holds true for many subgroups of patients. 13, 14 These studies also report that ≈70% of all multivessel disease patients undergoing PCI receive incomplete revascularization. 14 However, the studies did not conduct separate analyses for the subgroup of patients without STEMI, and they did not compare outcomes for patients undergoing CR in the index admission and patients obtaining CR in a subsequent staged admission.
The absence of evidence comparing 1-time CR and staged CR for patients without STEMI has led to considerable variation in treatment strategies for these patients.
A recent survey found that for patients with non-ST-elevation myocardial infarction/unstable angina, 42% of cardiologists would opt for treatment of the nonculprit lesion during the index admission, 37% would stage the second PCI at a later date, and 14% would only perform a second PCI if the patient developed persistent ischemia or symptoms. For patients with stable angina, these percentages were 50%, 21%, and 17%. 15 These findings indicate considerable practice pattern variation in the absence of evidence on the relative merits of the approaches, and our data on hospital variation also indicate considerable differences that seem to be unrelated to differences among patients. Although the predominant choice was to perform CR in the index admission when CR was undertaken, there were still quite a few hospitals that chose staging in another admission as a strategy. Although slightly >70% of all patients undergoing CR received it in the index admission, about one-sixth of the hospitals had risk-adjusted percentages of >90% for non-ACS, and more than one-third of the hospitals had risk-adjusted rates of >90% of their patients with ACS undergoing index admission CR.
Our objective in this study was to compare the strategy of CR with PCI in the index admission versus the strategy of staging in a subsequent admission for patients with coronary artery disease without STEMI. This was done for 2 separate groups: those with ACS but no STEMI, and those without ACS.
We found that among patients without STEMI who were treated with CR, 69.5% of non-ACS patients and 79.4% of ACS patients were treated with CR in the index admission. Also, we found no differences in 3-year mortality for patients with CR who were staged and unstaged, and this was true for patients without STEMI, regardless of whether they were patients with ACS or not. For propensity-matched patients without ACS, the all-cause mortality rates at 3 years for patients who were CR in the index hospitalization and patients staged for CR within 60 days of discharge were 5.62% and 5.97%; P=0.93, respectively. For propensity-matched patients with ACS, the all-cause mortality rates at 3 years for patients who were CR in the index hospitalization and patients staged for CR within 60 days of discharge were 6.59% and 5.92%; P=0.41, respectively. The mortality rates for the 2 groups were also very similar and not statistically different at 6 months, 1, and 2 years.
One of the most compelling reasons to compare 1-time CR with staging in a subsequent admission for patients without STEMI is cost. This is the motivation for the aforementioned bundling experiments of Centers for Medicare and Medicaid Services. 6 According to Blankenship et al, 16 the Medicare physician and hospital payments for single-stage multivessel PCI are $1276 and $15 573, respectively, for in-patient procedures and for staged procedures the respective payments are $1906 and $31 146. Thus, the respective physician and hospital payments are 49% and 100% higher for staged procedures than for single-stage procedures. The results of our study suggest that there is no mortality benefit to justify this extra cost. However, it could be justified on the basis of other outcome measures (eg, acute myocardial infarction, subsequent revascularization) not included in our study.
Limitations
A limitation of the study is that it is an observational study that is therefore susceptible to selection bias, whereby patients undergoing 1 of the 2 treatment options (eg, staged CR with PCI) could have been sicker in ways that were not measured and controlled for in the study. We attempted to minimize selection bias by using the best possible methods, including eliminating patients with characteristics that made them clearly inappropriate for single admission PCI with CR. These included patients with renal dialysis or severe renal dysfunction (glomerular filtration rate <30 mL/min per 1.73 m 2 ), complications after the first part of a staged procedure, and a high-contrast load (at least 5 mg/km) during the first part of a staged procedure.
Also, propensity matching of the remaining single admission and staged patients was done to guarantee that the matched pairs were extremely similar with regard to matched characteristics, and further minimization of differences among Three-year mortality for propensity-matched multivessel CAD patients with ACS. Log-rank test probability value =0.22. ACS indicates acute coronary syndrome; CAD, coronary artery disease; and CR, complete revascularization. February 2013 pairs in subgroup analyses was achieved by using Cox proportional hazards analyses on matched pairs. Patients who could not be matched closely were eliminated from the analyses.
Nevertheless, it is possible that some unmeasured confounders were present, and that they could have contributed to our findings. For example, we did not have data elements to capture frailty, risk of bleeding, or poor vascular access.
Furthermore, we were unable to compare outcomes for simple versus complex lesions or for appropriate versus inappropriate PCI based on appropriate use criteria because of lack of information in the databases we used. Also, mortality is the only outcome reported. Although renal and vascular complications were examined, they were too rare to achieve enough statistical power to compare the types of CR.
In conclusion, for patients without STEMI who undergo CR, 3-year mortality rates are not significantly different between staged and unstaged patients, and this holds true for ACS patients without STEMI as well as for patients without ACS. These findings are particularly important in view of the enormous cost savings that could be achieved by eliminating staging when it does not result in improved patient outcomes.
